How a Single Atom Decides Whether You See or Not express
Deep in the eye, in a thin layer of cells, a tiny molecular machine works. It captures light and turns it into a signal that the brain interprets as an image. But sometimes a typo occurs in the blueprints of this machine — a single letter of the genetic code changes, and a person is born blind.
For a long time, scientists couldn't understand why some typos completely break the machine while others merely slow it down. It turns out it's not about the mutation plugging an important hole like a cork. It's subtler: inside the protein, there's a tunnel through which a proton, a tiny particle, jumps from one place to another. This jump obeys the laws of the quantum world, where a particle can pass through barriers like a ghost through a wall. But if the wall becomes slightly thicker, by just a fraction of an atom, the probability of passage drops by hundreds and thousands of times.
To measure this effect, the researchers combined computer predictions of protein shape with quantum calculations. They introduced a simple metric, relative quantum activity, which shows how strongly a mutation weakens proton tunneling. This metric clearly separated patients into two groups: those with severe blindness and those with mild disease.
Now doctors will be able to predict in advance how severe the disease will be, simply by looking at the protein structure. And the approach itself, looking for "quantum cliffs" in proteins, could be useful for many other inherited diseases where fractions of an angstrom make all the difference.
Original abstract
as written by the authors arXiv:2601.18435
Predicting clinical severity from genotype remains a fundamental challenge in molecular medicine, particularly for enzymes whose function depends on sub-atomic-scale geometry. Mutations in the \textit{RPE65} isomerohydrolase cause Leber Congenital Amaurosis (LCA) and related retinal diseases; however, the kinetic mechanisms connecting sub-atomic-scale perturbations to blindness remain unclear. In this study, we demonstrate that mutations in the human visual isomerase RPE65 are governed by a quantum-mechanical threshold effect arising from proton tunneling in the active site. We established a hybrid quantum-classical structure-to-phenotype pipeline combining AlphaFold structure prediction with \textit{ab initio} quantum simulation using the Variational Quantum Eigensolver (VQE) to analyze minimal proton-coupled electron transfer in the visual cycle. Our analysis reveals that many pathogenic mutations do not merely occlude the active site, but rather strongly reduce the quantum probability of proton tunneling. We observed a sharp non-linear effect, termed the "Quantum Cliff," where minute structural changes (below 0.1 \AA) reduce the reaction rate by multiple orders of magnitude. Based on these findings, we introduce a dimensionless Relative Quantum Activity Score (RQAS) that isolates the geometry-controlled exponential sensitivity of the reaction rate and successfully distinguishes between mild and severe patient phenotypes. These results suggest that RPE65 operates near a quantum-critical point, where sub-Angstrom structural perturbations induce a catastrophic loss of function. Furthermore, our findings establish quantum tunneling as a predictive mechanistic link between atomic structure and clinical phenotype, proposing a general framework for quantum-structural disease modeling.
Protons don't just tunnel in the eye. Without quantum tunneling, the Sun wouldn't shine: it's how protons overcome electrical repulsion and trigger thermonuclear reactions.
In the series "The Expanse," the alien protomolecule rebuilds living organisms at the quantum level — much like RPE65 mutations change protein function due to quantum effects.